To date, there are only symptomatic treatments approved by the FDA and in wide clinical usage: Rivastigmine, Galantamine, Donepezil, and Memantine. However, their actual clinical efficacy has been questionable, due to wide variance in clinical response between the patients. In this review, the clinical efficacy and safety/tolerability between the three AchEIs (rivastigmine, galantamine, donepezil) and NMDA antagonist were compared.Additionally, the clinical efficacy of AchEI and memantine combination therapy has been reviewed.Safety and tolerability of the drugs were also compared by analyzing the incidence of adverse effects.Besides the standard treatment options, treatment of concomitant neuropsychiatric symptoms, and drugs under clinical trials have also been reviewed.